No Carolina / New York / Florida        Ph: 561.316.3330

Kevin Campbell Joins Vita Inclinata As Executive Vice President of Finance

What To Know

  • Kevin Campbell is an experienced financial executive with a strong mix of technical, operational, strategic, and commercial finance skills and a history of building, leading, and motivating teams in high-growth, investment-oriented businesses.
  • Kevin Campbell said, “I am impressed by Vita's life-saving technology and its impact within the aerospace and industrial markets and am excited to be part of an organization dedicated to saving lives.

Vita Inclinata (Vita), developer and producer of precision aerospace and industrial stabilization devices, today announced the appointment of Kevin Campbell as Executive Vice President of Finance.

Kevin Campbell is an experienced financial executive with a strong mix of technical, operational, strategic, and commercial finance skills and a history of building, leading, and motivating teams in high-growth, investment-oriented businesses.

Kevin Campbell’s goal at Vita is to create shareholder value by ensuring the company makes the best investment decisions to take advantage of its significant organic and acquisition-related growth opportunities. In addition, he will be focused on scaling the finance and accounting functions to support this rapid growth.

Kevin Campbell said, “I am impressed by Vita’s life-saving technology and its impact within the aerospace and industrial markets and am excited to be part of an organization dedicated to saving lives. My background in driving operational improvements, overseeing capital market and corporate development activities, and building teams will better position Vita for its next growth phase.”

Most recently, Campbell was Senior Vice President of Treasury and Corporate Development at Air Methods, which provides emergency medical services to over 100,000 patients annually in 48 states. In this position, he was responsible for capital and investment management, corporate development, capital market activities, treasury, and investor relations. He also previously served as the Senior Vice President of Corporate Finance at Air Methods where he managed the annual budget, quarterly forecast, and management reporting processes, among other things. Before joining Air Methods, Campbell served as Managing Director at Avondale Partners, a boutique investment bank where he wrote research on publicly-traded companies. He began his career at Greenwich Alternative Investments, where he was responsible for qualitative research on hedge funds, managing three funds that invested in other hedge funds, and the firm’s relationships with its largest institutional investors.

“Kevin Campbell’s leadership experience and ability to position corporate financial systems for notable growth is an outstanding addition to our executive team,” said Caleb Carr, CEO of Vita. “His demonstrated experience financially guiding an aviation medical company to national success parallels Vita’s growth goals. We are eager to benefit from the dividends his experience will bring to our organization.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Movers & Shakerss

Avation Medical adds Vice President of Market Access

“Adding Michael to the Avation leadership team is our next step in launching Vivally,” said Jill Schiaparelli, founder and CEO of Avation Medical. “Patients have been crystal clear that they want a surgical-free, non-invasive treatment option for their OAB symptoms. Our focus now is to ensure that Vivally is easily accessible to the 46 million patients suffering from OAB in this country.”

Xeno Biosciences Welcomes New CEO, Dennis D. Kim, MD, MBA Plus Secures Funding

Dennis has an extraordinary depth of knowledge and is highly respected in the obesity field; I could not imagine anyone more perfect to lead our company,” said Jeff Arnold, Chairman and a Director at Xeno Biosciences since 2017.

Peter Eckes, Former CTO of BASF Agricultural Solutions, to Chair Harpe Bioherbicide Board

Peter Eckes offers more than a 30-year career in the agricultural industry, and provides a unique appreciation for what it takes to bring innovation to the modern agriculture marketplace at scale without losing sight of farmer and consumer needs.

Related Articles

By using this website you agree to accept Medical Device News Magazine Privacy Policy